-+ 0.00%
-+ 0.00%
-+ 0.00%

Stifel Maintains Buy on Structure Therapeutics, Raises Price Target to $90

Benzinga·12/09/2025 13:56:10
Listen to the news
Stifel analyst Annabel Samimy maintains Structure Therapeutics (NASDAQ:GPCR) with a Buy and raises the price target from $50 to $90.